These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24727144)

  • 21. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
    Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
    J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum.
    Chowdhury F; Tutt AL; Chan C; Glennie M; Johnson PW
    J Immunol Methods; 2010 Dec; 363(1):1-8. PubMed ID: 20869964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia.
    Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S
    PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
    Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
    MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD
    Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN
    Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexmedetomidine and hydromorphone: a novel pain management strategy for the oncology ward setting during anti-GD2 immunotherapy for high-risk neuroblastoma in children.
    Görges M; West N; Deyell R; Winton P; Cheung W; Lauder G
    Pediatr Blood Cancer; 2015 Jan; 62(1):29-34. PubMed ID: 25263424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival.
    Cheung NK; Cheung IY; Canete A; Yeh SJ; Kushner B; Bonilla MA; Heller G; Larson SM
    Cancer Res; 1994 Apr; 54(8):2228-33. PubMed ID: 8174131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
    Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
    Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
    Handgretinger R; Anderson K; Lang P; Dopfer R; Klingebiel T; Schrappe M; Reuland P; Gillies SD; Reisfeld RA; Neithammer D
    Eur J Cancer; 1995; 31A(2):261-7. PubMed ID: 7718335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.
    Saleh MN; Khazaeli MB; Wheeler RH; Allen L; Tilden AB; Grizzle W; Reisfeld RA; Yu AL; Gillies SD; LoBuglio AF
    Hum Antibodies Hybridomas; 1992 Jan; 3(1):19-24. PubMed ID: 1576319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells.
    Barker E; Mueller BM; Handgretinger R; Herter M; Yu AL; Reisfeld RA
    Cancer Res; 1991 Jan; 51(1):144-9. PubMed ID: 1988079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
    Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
    Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
    Cheung NK; Guo HF; Heller G; Cheung IY
    Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pain outcomes between two anti-GD2 antibodies in patients with neuroblastoma.
    Anghelescu DL; Goldberg JL; Faughnan LG; Wu J; Mao S; Furman WL; Santana VM; Navid F
    Pediatr Blood Cancer; 2015 Feb; 62(2):224-228. PubMed ID: 25382742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.
    Simon T; Hero B; Faldum A; Handgretinger R; Schrappe M; Klingebiel T; Berthold F
    BMC Cancer; 2011 Jan; 11():21. PubMed ID: 21244693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
    Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
    Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.